Introducing ALZpath
Transforming the Alzheimer’s disease ecosystem
Introducing ALZpath
Transforming the Alzheimer’s disease ecosystem.
ALZpath is a passionate and focused group of medical researchers, healthcare professionals, and renowned scientific advisors dedicated to transforming the Alzheimer’s disease ecosystem through earlier diagnosis, intervention, and personalized treatment to improve outcomes for people with Alzheimer’s.
Launching a novel blood-based biomarker assay for phosphorylated tau 217 (ptau217), ALZpath offers a simple, accessible, timely, and cost-effective approach to diagnosis, which is less invasive than current testing methods. Ptau217 in blood is considered one of the transformative AD diagnostic biomarker, which closely reflects amyloid and tau pathology, the hallmarks of AD, and correlates with clinical features of AD.
Removing barriers to improve Alzheimer’s disease outcomes
Early diagnosis and treatment, along with the integration of patient, family, care partner, and provider needs, lead to improved Alzheimer’s disease outcomes. Current wait times vary from months to years to access the medical specialists necessary to make an accurate Alzheimer’s disease diagnosis. Additionally, the cost of the specific tests currently required for an accurate diagnosis may result in significant out-of-pocket expenses that are beyond the reach of many patients. ALZpath is pioneering a better path – A path that will ultimately transform the Alzheimer’s disease ecosystem.
A new path forward for those who need it most
ALZpath is for people looking for
Answers about memory and thinking concerns
Better outcomes at a cost they can afford
Guidance on meeting their needs now and in the future
Support to build a post-diagnosis path forward
ALZpath is for clinicians
ALZpath provides Alzheimer’s disease expertise, assessment, testing tools, and post-diagnostic guidance to assist non-dementia trained providers in meeting the needs of people expressing subjective cognitive concerns. ALZpath is the AD expert referral site for your patients
Because ALZpath is a virtual service, we can meet the needs of your patients who may be facing geographic or transportation challenges
ALZpath provides answers for your patients rapidly
Using a blood-based biomarker and cognitive assessment, ALZpath may reduce unnecessary specialist visits.
ALZpath is for people looking for
Answers about memory and thinking concerns
Better outcomes at a cost they can afford
Guidance on meeting their needs now and in the future
Support to build a post-diagnosis path forward
ALZpath is for clinicians
ALZpath provides Alzheimer’s disease expertise, assessment, testing tools, and post-diagnostic guidance to assist non-dementia trained providers in meeting the needs of people expressing subjective cognitive concerns. ALZpath is the AD expert referral site for your patients
Because ALZpath is a virtual service, we can meet the needs of your patients who may be facing geographic or transportation challenges
ALZpath provides quick answers for your patients
Using a blood-based biomarker and cognitive assessment, ALZpath may reduce unnecessary specialist visits.
ALZpath creates a comprehensive solution for providers and patients
ALZpath PathFinders is a virtual team of Alzheimer’s disease experts providing cognitive assessments, results consultations, and assistance in building a path forward for people with Alzheimer’s disease. PathFinders integrate biomarkers, cognitive assessments, education, and ongoing patient guidance in a comprehensive diagnosis, care, research, and treatment approach. PathFinder tools include:
Blood-Based Biomarkers for the early diagnosis of Alzheimer’s disease
Connection with clinical trial selection and enrollment
Lifestyle modification support aimed at reducing cognitive decline
Patient, care partner, and clinician education on Alzheimer’s disease
Strategies to successfully live with and manage Alzheimer’s disease
Take the first step towards better Alzheimer’s disease outcomes
ALZpath, Inc. has developed a novel, validated assay for p-tau 217 for use in blood and cerebrospinal fluid that is now available for research and clinical trials. It will be available for clinical use in the second half of 2022.
If you are interested in joining this rapidly growing collaborative network by becoming an early customer or research partner, please complete the form below to obtain additional information.
Together, we can pioneer a better healthcare experience by integrating clinical expertise, technology, bespoke services, support, and most importantly, an intense passion and focus on making a real difference in people’s lives.
Please join us in the journey to make a lasting difference in the lives of those impacted by Alzheimer’s disease.
I’d like to learn more about ALZpath:
